Physician profile
Michael Keith Ackerman
NPI 1174687917
$134,319.07
in general payments reported to CMS, 2019-2025
12 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.91 · 2020: $10K · 2021: $17K · 2022: $26K · 2023: $27K · 2024: $32K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $2,501 · Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,812.50 |
| Travel and Lodging | $2,500.89 |
| Food and Beverage | $808.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $13,733.27 | 2025 | Vyvgart Hytrulo |
| Emd Serono, INC. | $2,850.00 | 2021 | |
| Novartis Pharma Ag | $2,475.00 | 2021 | |
| Alkermes, INC. | $1,900.00 | 2020 | |
| Abbott Laboratories | $1,304.07 | 2021-2025 | Alere Cholestech Ldx, Afinion 2, Afinion Hba1c Dx |
| Amgen INC. | $54.12 | 2025 | Evenity, Prolia |
| Dexcom, INC. | $45.50 | 2022-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $34.71 | 2019 | |
| Pfizer INC. | $28.67 | 2025 | |
| Sanofi-Aventis U.S. LLC | $21.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.70 | 2023 | |
| Medtronic, INC. | $13.57 | 2024 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.